Research Article

Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS

Volume: 40 Number: 2 July 19, 2023
EN

Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS

Abstract

Background/aim: In recent years, studies have focused on new markers to predict the risk of cardiovascular diseases (CVD). There are several studies analyzing biomarkers such as myeloperoxidase (MPO), suppression of tumorgenicity 2 (sST2), and osteopontin (OPN) in CVD, however, there are no studies that show their relationship in patients who have fragmented QRS (fQRS). It was aimed to investigate the OPN, sST2, and MPO levels in patients who were diagnosed with the acute coronary syndrome (ACS) in the present study. Materials and Methods: Sixty ACS patients and 26 healthy individuals were included in the study. Patients diagnosed ACS were divided into two groups as (+)fQRS (n=30) and (-)fQRS (n=30). Levels of OPN and sST2 were measured by ELISA, and also MPO was measured by colorimetric methods. Results: In ACS patients, serum MPO (33.7 U/L), OPN (103.29 ng/mL) and sST2 (495.4 pg/mL) levels were found significantly higher than the control group (23.14 U/L, 42.65 ng/mL, 344.11 pg/mL, respectively; p<0.01, p<0.01, p<0.05). However, there were no significant differences between MPO, OPN and sST2 levels in patients with (+)fQRS (respectively, 32.74 U/L, 101.89 ng/mL and 451.97 pg/mL) and (-)fQRS (respectively, 34.67 U/L, 104.69 ng/mL, 535.73 pg/mL). There were also positive correlations between MPO and platelet (r=0.376, p<0.05) levels in the (+)fQRS group, and sST2 and triglyceride levels in the (-)fQRS group. When the diagnostic performances for ACS were examined, the sensitivity of CK-MB, troponin-I, MPO, OPN and sST2 were 83%, 80%, 65%, 85%, 58% and specificity 96%, 100%, 72%, 96%, 80%, respectively. Conclusions: In conclusion, MPO, OPN, and sST2 may be included in the factors that may contribute to the diagnosis and development of ACS. In addition, the discovery of the high diagnostic sensitivity and specificity of OPN in acute coronary syndrome is a new finding obtained in this study.

Keywords

Supporting Institution

This study was supported by Ordu University Scientific Research Projects Coordination Department

Project Number

Project Number: B-1905

Thanks

The authors would like to thank Assistant Professor Sıddık Keskin, Van Yuzuncu Yil University, Van/ Türkiye, for helping statistical analysis.

References

  1. Take Y, Morita H. Fragmented QRS: What Is The Meaning? Indian Pacing Electrophysiol J. 2012 Sep;12(5):213-25. doi: 10.1016/s0972-6292(16)30544-7. Epub 2012 Sep 1. PMID: 23071383; PMCID: PMC3443879.
  2. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B. doi: 10.1016/j.amjcard.2015.01.034. Epub 2015 Jan 23. PMID: 25665766.
  3. Binas D, Daniel H, Richter A, Ruppert V, Schlüter KD, Schieffer B, Pankuweit S. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart. 2018 Feb 26;5(1):e000750. doi: 10.1136/openhrt-2017-000750. PMID: 29531765; PMCID: PMC5845404.
  4. You H, Jiang W, Jiao M, Wang X, Jia L, You S, Li Y, Wen H, Jiang H, Yuan H, Huang J, Qiao B, Yang Y, Jin M, Wang Y, Du J. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy. Can J Cardiol. 2019 Jun;35(6):727-735. doi: 10.1016/j.cjca.2019.02.016. Epub 2019 Feb 27. PMID: 31151708.
  5. Aimo A, Migliorini P, Vergaro G, Franzini M, Passino C, Maisel A, Emdin M. The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? Int J Cardiol. 2018 Sep 15;267:188-192. doi: 10.1016/j.ijcard.2018.05.056. Epub 2018 May 19. PMID: 29793758.
  6. Mohamadpour AH, Abdolrahmani L, Mirzaei H, Sahebkar A, Moohebati M, Ghorbani M, Ferns GA, Ghayour-Mobarhan M. Serum osteopontin concentrations in relation to coronary artery disease. Arch Med Res. 2015 Feb;46(2):112-7. doi: 10.1016/j.arcmed.2015.02.005. Epub 2015 Mar 2. PMID: 25743929.
  7. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993 Oct;92(4):1686-96. doi: 10.1172/JCI116755. PMID: 8408622; PMCID: PMC288328.
  8. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal. 2009 Nov;11(11):2899-937. doi: 10.1089/ars.2009.2538. Erratum in: Antioxid Redox Signal. 2010 Feb;12(2):322. Augusto, Ohara [removed];Chen, John W [removed]; Davies, Michael [removed]; Ma,Xin-Liang [removed]; Malle, Ernst [removed]; Pignatelli, Pasquale [removed]; Rudolph, Tanja [removed]. PMID: 19622015.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Early Pub Date

August 1, 2023

Publication Date

July 19, 2023

Submission Date

October 17, 2022

Acceptance Date

February 15, 2023

Published in Issue

Year 2023 Volume: 40 Number: 2

APA
Noyan, T., Memecan, S. S., & Bektaş, O. (2023). Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS. Deneysel Ve Klinik Tıp Dergisi, 40(2), 225-231. https://izlik.org/JA67CB86MH
AMA
1.Noyan T, Memecan SS, Bektaş O. Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS. J. Exp. Clin. Med. 2023;40(2):225-231. https://izlik.org/JA67CB86MH
Chicago
Noyan, Tevfik, Seda Suzan Memecan, and Osman Bektaş. 2023. “Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients With Fragmented QRS”. Deneysel Ve Klinik Tıp Dergisi 40 (2): 225-31. https://izlik.org/JA67CB86MH.
EndNote
Noyan T, Memecan SS, Bektaş O (July 1, 2023) Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS. Deneysel ve Klinik Tıp Dergisi 40 2 225–231.
IEEE
[1]T. Noyan, S. S. Memecan, and O. Bektaş, “Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS”, J. Exp. Clin. Med., vol. 40, no. 2, pp. 225–231, July 2023, [Online]. Available: https://izlik.org/JA67CB86MH
ISNAD
Noyan, Tevfik - Memecan, Seda Suzan - Bektaş, Osman. “Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients With Fragmented QRS”. Deneysel ve Klinik Tıp Dergisi 40/2 (July 1, 2023): 225-231. https://izlik.org/JA67CB86MH.
JAMA
1.Noyan T, Memecan SS, Bektaş O. Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS. J. Exp. Clin. Med. 2023;40:225–231.
MLA
Noyan, Tevfik, et al. “Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients With Fragmented QRS”. Deneysel Ve Klinik Tıp Dergisi, vol. 40, no. 2, July 2023, pp. 225-31, https://izlik.org/JA67CB86MH.
Vancouver
1.Tevfik Noyan, Seda Suzan Memecan, Osman Bektaş. Osteopontin, Suppression of Tumorgenicity 2 and Myeloperoxidase Levels in Acute Coronary Syndrome Patients with Fragmented QRS. J. Exp. Clin. Med. [Internet]. 2023 Jul. 1;40(2):225-31. Available from: https://izlik.org/JA67CB86MH